Shares of Schmid Group (SHMD) fell 11.4% to $5.64, pressured by broader market declines and weakening technical momentum. The stock is trading below its 20-day and 100-day moving averages, signaling short-term bearishness, though it remains above its 200-day average, indicating no long-term breakdown yet. Key support is at $5.50, with resistance near $6.00. Market conditions, including a down Russell 2000 and defensive sector underperformance, are contributing to the stock's decline. Investors should watch if SHMD breaks below support or recovers above resistance to gauge future momentum.
Prestige Consumer Healthcare completed the acquisition of Australian therapeutic skin care company LaCorium Health for approximately $150 million in cash on July 1, 2026. LaCorium, known for brands like Dermal Therapy and Flexitol, generates about $4...
GuideAI Health Corp. has appointed Dr. James F. Benenati, a leading interventional radiologist, to its Advisory Board following FDA 510(k) clearance of its AI software, VascularAssist Occlusion Triage (VAOT). VAOT is designed to help radiologists pri...
Diginex Limited has agreed with Resulticks to extend the deadline for their acquisition deal to July 31, 2026, after securing firm funding intent from private investors. The company does not plan to seek public funding and expects this to be the fina...
Rogers Communications has agreed to buy the remaining 25% stake in Maple Leaf Sports & Entertainment (MLSE) from Kilmer Sports for C$4.35 billion, making Rogers the sole owner. This move aims to strengthen Rogers' position in Canadian sports and ente...
VERAXA Biotech updated on its progress in developing novel cancer therapies using its proprietary BiTAC platform, focusing on conditionally active T cell engagers and bispecific antibody-drug conjugates. The company plans to prioritize investment in ...
